医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Ferring announces second $3 million donation to the Royal Textile Academy of Bhutan

2013年06月05日 PM09:25
このエントリーをはてなブックマークに追加


 

SAINT PREX, Switzerland

Ferring Pharmaceuticals has announced a second $3 million donation to the Royal Textile Academy of Bhutan to support its mission to preserve and promote Bhutanese textiles and improve the livelihoods of the weavers who make them.

Today, at the opening of the new Royal Textile Academy facilities in Thimphu, Bhutan, Michel Pettigrew, President of the Ferring Executive Board, said “We are very keen that this major cultural initiative of preserving Bhutan’s traditional skills and heritage continues, and that the commercial momentum which will enhance the quality of life and economic prospects of the weavers be able to grow over the next few years. This is of great importance to all of us at Ferring as we conduct our business under the Philosophy of “People Come First.”

In 2009, Ferring donated $3 million to the Academy to fund the creation of a new cultural centre in the Bhutanese capital of Thimphu. The new grant will be used to support the continued development of the academy, which includes a state-of-the-art museum, a textile weaving school and conservation centre.

On behalf of Her Majesty, Gyalyum Sangay Choden Wangchuck, Mrs. Rinzin O. Dorji, Executive Director of the Academy, thanked Ferring and said “This grant will not only benefit the weavers of Bhutan, through the academy it will contribute to economic development in the region.”

– Ends –

About Ferring Pharmaceuticals:

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of gastroenterology, reproductive health, urology and endocrinology. Ferring has its own operating subsidiaries in 50 countries and markets its products in more than 90 countries. To learn more about Ferring or its products please visit www.ferring.com.

CONTACT

For further information, contact:
Helen Gallagher
Tel. +41 (0)
58 301 00 51
helen.gallagher@ferring.com
or
Patrick
Gorman
Tel: +41 (0) 58 301 00 53
patrick.gorman@ferring.com

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続